Tamara Garrido

Dr Garrido is a reproductive biologist working with a special focus on endometrial physiology, embryo implantation and pregnancy complications. She graduated in Biological Sciences (2002-2007) at the University of Valencia, with the highest qualification: the “extraordinary award”. In 2012, she completed her PhD, qualifying with the highest degree Cum Laude, guided by Professor Carlos Simón at the Faculty of Medicine at the University of Valencia‘, supported by the FPU program from the Ministry of Education and Sciences.

The expertise obtained during her PhD allowed her to start a post-doctoral investigation on endometrial pathologies in the context of pregnancy complications, forming part of the INCLIVA Biomedical Research Institute from 2013. The first phase of her post-doctoral fellowship was supported by the program VALi+d from Valencian Generalitat. In her second postdoctoral phase, she was awarded the prestigious Sara Borrell research fellowship from the Institute of Health Carlos III.

During her post-doctoral training she moved to the laboratory of Susan Fisher at the University California, San Francisco (UCSF) in the USA. Her stay (2.5 years) allowed her to become a specialist in the study of pre-eclampsia disease, and specifically in the role of the maternal uterus in the development of pre-eclampsia. She has published high-impact peer-reviewed publications in prestigious journals such as PNAS, Development, The Journal of Clinical Endocrinology and Metabolism (JCEM), Federation of American Societies for Experimental Biology journal (FASEB), and Human Reproduction, among others, and she is a regular contributor to and reviewer of international journals. To date, she has supervised a medical student in her final project and directed one doctoral thesis; she has participated in four national projects, one of them as principal investigator; and has participated in over 14 international conferences.

Currently, she is working at Igenomix Foundation as a researcher in the R&D department and her efforts are focused on the investigation of maternalfetal interface communications and their role during healthy pregnancies and those with complications.